Incidental diffuse low-grade gliomas: A systematic review and meta-analysis of treatment results with correction of lead-time and length-time biases.
incidental
lead-time bias
length-time bias
low-grade glioma
meta-analysis
Journal
Neuro-oncology practice
ISSN: 2054-2577
Titre abrégé: Neurooncol Pract
Pays: England
ID NLM: 101640528
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
entrez:
27
3
2023
pubmed:
28
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
Better overall survival (OS) reported in patients with incidental diffuse low-grade glioma (iLGG) in comparison to symptomatic LGG (sLGG) may be overestimated by lead-time and length-time. We performed a systematic review and meta-analysis of studies on adult hemispheric iLGGs according to the PRISMA statement to adjust for biases in their outcomes. Survival data were extracted from Kaplan-Meier curves. Lead-time was estimated by 2 methods: Pooled data of time to become symptomatic (LTs) and time calculated from the tumor growth model (LTg). We selected articles from PubMed, Ovid Medline, and Scopus since 2000. Five compared OS between patients with iLGG ( The reported outcome in iLGG was biased by lead-time and length-time. Although iLGG had a longer OS after correction of biases, the difference was less than previously reported.
Sections du résumé
Background
UNASSIGNED
Better overall survival (OS) reported in patients with incidental diffuse low-grade glioma (iLGG) in comparison to symptomatic LGG (sLGG) may be overestimated by lead-time and length-time.
Methods
UNASSIGNED
We performed a systematic review and meta-analysis of studies on adult hemispheric iLGGs according to the PRISMA statement to adjust for biases in their outcomes. Survival data were extracted from Kaplan-Meier curves. Lead-time was estimated by 2 methods: Pooled data of time to become symptomatic (LTs) and time calculated from the tumor growth model (LTg).
Results
UNASSIGNED
We selected articles from PubMed, Ovid Medline, and Scopus since 2000. Five compared OS between patients with iLGG (
Conclusions
UNASSIGNED
The reported outcome in iLGG was biased by lead-time and length-time. Although iLGG had a longer OS after correction of biases, the difference was less than previously reported.
Identifiants
pubmed: 36970177
doi: 10.1093/nop/npac073
pii: npac073
pmc: PMC10037942
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
113-125Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Ann Neurol. 2007 May;61(5):484-90
pubmed: 17469128
J Neurosurg. 2018 Jul;129(1):19-26
pubmed: 28984519
BMC Med Res Methodol. 2005 Apr 20;5:13
pubmed: 15840177
PLoS One. 2018 Sep 20;13(9):e0203639
pubmed: 30235224
Neurol Med Chir (Tokyo). 2001 Sep;41(9):431-4; discussion 435
pubmed: 11593969
Liver Cancer. 2020 Dec;9(6):744-755
pubmed: 33442543
Onco Targets Ther. 2020 Sep 25;13:9533-9542
pubmed: 33061437
Neuro Oncol. 2015 Mar;17(3):332-42
pubmed: 25087230
PLoS One. 2016 Mar 07;11(3):e0151080
pubmed: 26950220
Neuro Oncol. 2020 Dec 18;22(12):1822-1830
pubmed: 32328652
Acta Neurochir (Wien). 2021 Dec;163(12):3401-3415
pubmed: 34227013
Neurosurgery. 2020 Mar 1;86(3):391-399
pubmed: 31260076
Acta Neurochir (Wien). 2013 Dec;155(12):2237-42
pubmed: 24085316
Neurosurg Focus. 2011 Dec;31(6):E12
pubmed: 22133169
Neurosurgery. 2021 Mar 15;88(4):797-803
pubmed: 33372205
Sci Rep. 2021 Apr 19;11(1):8522
pubmed: 33875775
World Neurosurg. 2022 Mar;159:e347-e355
pubmed: 34942387
J Neurosurg. 2020 Oct 2;:1-8
pubmed: 33007758
Neuro Oncol. 2022 Apr 1;24(4):624-638
pubmed: 34498069
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Neurol Med Chir (Tokyo). 2022 Apr 15;62(4):177-185
pubmed: 35197400
World Neurosurg. 2019 Dec;132:e133-e139
pubmed: 31505287
Ann Neurol. 2010 Nov;68(5):727-33
pubmed: 21031584
Int J Clin Exp Pathol. 2014 Dec 01;7(12):8627-36
pubmed: 25674227
J Neurooncol. 2018 Aug;139(1):167-175
pubmed: 29633111
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
Stat Methods Med Res. 2020 Feb;29(2):374-395
pubmed: 30854935
J Clin Oncol. 2008 Mar 10;26(8):1338-45
pubmed: 18323558
J Neurosurg. 2015 Jun;122(6):1397-405
pubmed: 25723301
Onco Targets Ther. 2012;5:357-61
pubmed: 23180968
Neurosurgery. 2020 Sep 15;87(4):720-729
pubmed: 31813972
Am Fam Physician. 2014 Nov 1;90(9):625-31
pubmed: 25368922
Oxf Med Case Reports. 2014 Aug 12;2014(5):96-7
pubmed: 25988042
BMC Pulm Med. 2021 Jan 6;21(1):4
pubmed: 33407288
J Neurooncol. 2012 May;108(1):69-75
pubmed: 22392125
J Nucl Med. 2008 May;49(5):730-7
pubmed: 18413396
Am J Epidemiol. 2008 Jul 1;168(1):98-104
pubmed: 18504245
Eur J Radiol. 2009 Oct;72(1):54-64
pubmed: 18632238
J Neurosurg. 2012 Feb;116(2):365-72
pubmed: 21999317